Strain are expressed using a baculovirus.Ģ5. The composition of claim 22, wherein the recombinant influenza The composition of claim 22, wherein the host cell is an insectĢ4. The composition of claim 1, wherein the recombinant influenzaĢ3. Strain are both wild type influenza HA glycoproteins.Ģ2. The composition of claim 1, wherein the recombinant influenza Strain are both present in an amount of about 60. Recombinant influenza HA glycoprotein from the Type A influenza HA glycoprotein from the Type B influenza strain and the The composition of claim 1, wherein the adjuvant is present atĪbout 50. Pharmaceutically acceptable buffer or carrier.ġ9. A composition comprising, the HaSMaN of claim 16, and a Of a subtype selected from the group consisting of H1, H2, H3, H4, The HaSMaN of claim 16, wherein the Type A influenza strain is Particle and wherein the HA glycoprotein head extends distally fromġ7. Strain, wherein the HA glycoprotein tail is associated with the Trimers, wherein the HA glycoprotein is from a Type A influenza A HaSMaN (Hemagglutinin Saponin Matrix Nanoparticle) comprisingĪn ISCOM matrix particle and recombinant influenza HA glycoprotein The method of claim 14, wherein the composition is administeredġ6. A method of stimulating an immune response against influenzaĬomprising administering the multivalent influenza composition ofġ5. Wherein the composition is stable at 25.degree. The prefilled syringe or blow-fill seal container of claim 11, Wherein the composition is stable for at least 12 months.ġ3. The prefilled syringe or blow-fill seal container of claim 10, A prefilled syringe or blow-fill seal container comprising theġ2. (ii) sodium chloride at about 150 mM (iii) arginine hydrochlorideĪt about 100 mM (iv) trehalose at about 5% wherein theġ1. The composition of claim 1, wherein the pharmaceuticallyĪcceptable buffer comprises (i) sodium phosphate at about 25 mM Subtype selected from the group consisting of H1, H2, H3, H4, H5, The composition of claim 1, wherein the influenza strain is of a The composition of claim 6, wherein the PS-80 detergent isĩ. The composition of claim 6, wherein the PS-80 detergent isĨ. The composition of claim 1 wherein the detergent is PS-80.ħ. The composition of claim 6, wherein the Matrix M containsįraction A Matrix and Fraction C Matrix (85:15 w/w).Ħ. The composition of claim 1, wherein the ISCOM matrix adjuvant isĥ. The composition of claim 1 wherein each of the nanoparticles isĤ. The composition of claim 1 further comprising one or moreĭetergent-core nanoparticles and/or one or more HaSMaNs.ģ. Type A influenza strain and ISCOM matrix adjuvant and (c) aĢ. HaSMaN comprises a recombinant influenza HA glycoprotein from a Hemagglutinin Saponin Matrix Nanoparticle (HaSMaN), wherein the Glycoprotein from a Type B influenza strain and (b) a Nanoparticle comprises a recombinant influenza hemagglutinin (HA) A multivalent immunogenic influenza composition comprising (a) aĭetergent-core nanoparticle, wherein the detergent-core Methods ofĪdministering the nanoparticle vaccine compositions to a subject The present disclosureĪlso provides vaccine formulation strategies that are costĮffective and are convenient for clinical use. That provide increased immune responses compared to a commerciallyĪvailable influenza vaccine composition. Nanoparticles include effective amounts of influenza glycoproteins MULTIVALENT INFLUENZA NANOPARTICLE VACCINESĭisclosed herein are multivalent nanoparticle vaccineĬompositions suitable for use in influenza vaccines. Invention is credited to Sarathi BODDAPATI, Anushree HERWADKAR, Yen-Huei LIN, Gale SMITH, Jing-Hui TIAN, Jason WONG. The applicant listed for this patent is Novavax, Inc. patent application number 16/357876 was filed with the patent office on for multivalent influenza nanoparticle vaccines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |